Prevalence of primary HIV-1 drug resistance among recently infected adolescents: A Multicenter Adolescent Medicine Trials Network for HIV/AIDS Interventions Study

Journal of Infectious Diseases

Volumn 194, Issue 11, 2006, Pages 1505-1509

  Viani, Rolando M ^a   Peralta, Ligia ^c   Aldrovandi, Grace ^b   Kapogiannis, Bill G ^d   Mitchell, Rick ^e   Spector, Stephen A ^a   Lie, Yolanda S ^f   Weidler, Jodi M ^f   Bates, Michael P ^f   Liu, Nancy ^e   Wilson, Craig M ^g  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c UNIVERSITY OF MARYLAND   (United States)

^d EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^e WESTAT   (United States)

^f Monogram Biosciences Inc   (United States)

^g UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; AMPRENAVIR; ANTIRETROVIRUS AGENT; ASPARAGINE; ATAZANAVIR; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; INDINAVIR; LAMIVUDINE; LOPINAVIR; LYSINE; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TENOFOVIR; TIPRANAVIR; ZIDOVUDINE;

ADOLESCENT; ADULT; ANTIBIOTIC RESISTANCE; ARTICLE; CD4 LYMPHOCYTE COUNT; DRUG SENSITIVITY; FEMALE; GENE MUTATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IC 50; MAJOR CLINICAL STUDY; MALE; MULTIDRUG RESISTANCE; NUCLEOTIDE SEQUENCE; PHENOTYPE; PRIORITY JOURNAL; SCHOOL CHILD; UNITED STATES; VIRUS LOAD;

ADOLESCENT; ADULT; AMINO ACID SUBSTITUTION; ANTI-HIV AGENTS; CHILD; DRUG RESISTANCE, VIRAL; FEMALE; HIV INFECTIONS; HIV PROTEASE; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; MALE; MUTATION;

EID: 33845213744     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/508749     Document Type: Article

References (15)

1. Palella FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338:853-60.
2. Lorenzi P, Opravil M, Hirschel B, et al. Impact of drug resistance mutations on virologic response to salvage therapy. Swiss HIV Cohort Study. AIDS 1999; 13:F17-21.
3. Little SJ, Holte S, Routy JP, et al. Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med 2002; 347:385-94.
4. Descamps D, Chaix ML, Andre P, et al, French national sentinel survey of antiretroviral drug resistance in patients with HIV-1 primary infection and in antiretroviral-naive chronically infected patients in 2001-2002. J Acquir Immune Defic Syndr 2005; 38:545-52.
5. Wensing AM, van de Vijver DA, Angarano G, et al. Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: implications for clinical management. J Infect Dis 2005; 192:958-66.
6. Rawal BD, Degula A, Lebedeva L, et al. Development of a new less-sensitive enzyme immunoassay for detection of early HIV-1 infection. J Acquir Immune Defic Syndr 2003; 33:349-55.
7. Johnson VA, Brun-Vezinet F, Clotet B, et al. Update of the drug resistance mutations in HIV-1: 2005. Top HIV Med 2005; 13:51-7.
8. Petropoulos CJ, Parkin NT, Limoli KL, et al. A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1. Antimicrob Agents Chemother 2000; 44:920-8.
9. Center for Disease Control and Prevention. HIV/AIDS surveillance report, 2003. Available at: http://www.cdc.gov/hiv/stats/hasrlink.htm. Accessed 5 December 2005.
10. Grant RM, Hecht FM, Warmerdam M, et al. Time trends in primary HIV-1 drug resistance among recently infected persons. JAMA 2002; 288:181-8.
11. Center for Disease Control and Prevention. Trends in HIV/AIDS diagnosis: 33 states, 2001-2004. MMWR Morb Mortal Wkly Rep 2005;54: 1149-53.
12. Madec Y, Boufassa F, Rouzioux C, Delfraissy JF, Meyer L. Undetectable viremia without antiretroviral therapy in patients with HIV seroconversion: an uncommon phenomenon? Clin Infect Dis 2005; 40:1350-4.
13. Barbour JD, Hecht FM, Wrin T, et al. Persistence of primary drug resistance among recently HIV-1 infected adults. AIDS 2004; 18:1683-9.
14. McGowan JP, Shah SS, Ganea CE, et al. Risk behavior for transmission of human immunodeficiency virus (HIV) among HIV-seropositive individuals in an urban setting. Clin Infect Dis 2004; 38:122-7.
15. Hirsch MS, Brun-Vezinet F, Clotet B, et al. Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA Panel. Clin Infect Dis 2003; 37:113-28.